PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma

ERK pathway regulated the programmed death ligand-1 (PD-L1) expression which was linked to the response of programmed death-1 (PD-1)/PD-L1 blockade therapy. So it is deducible that ERK inhibitor could enhance the efficacy of PD-1 inhibitor in cancer immunotherapy. In this study, PD0325901, an oral p...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Min, Xia, Yuhui, Wang, Fang, Zhang, Hong, Su, Danting, Su, Chaoyue, Yang, Chuan, Wu, Shaocong, An, Sainan, Lin, Suxia, Fu, Liwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546891/
https://www.ncbi.nlm.nih.gov/pubmed/34729305
http://dx.doi.org/10.1016/j.apsb.2021.03.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546891/
https://www.ncbi.nlm.nih.gov/pubmed/34729305
http://dx.doi.org/10.1016/j.apsb.2021.03.010

Ejemplares similares